IMPORTANT INVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Akari Therapeutics, Plc and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, May 19, 2017 /PRNewswire/ -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Akari Therapeutics, Plc ("Akari" or the "Company") (Nasdaq: AKTX) concerning possible violations of federal securities laws between March 30, 2017 and May 11, 2017  inclusive (the "Class Period"). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the July 11, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, throughout the Class Period, Akari made materially false and/or misleading statements, and/or failed to disclose materially adverse facts about its business, operations, and prospects. On April 26, 2017, Edison Research Ltd. issued a report on the Company called "Akari's Coversin matches Soliris in Phase II." The next day it was announced that the report was withdrawn due to "material inaccuracies." On May 11, 2017, Akari announced that CEO Dr. Gur Roshwalb has been placed on administrative leave while the Board of Directors reviews whether Dr. Roshwalb and other executives were involved with the materially inaccurate research report. Upon release of this information, Akari shares fell in value, which harmed investors according to the Complaint.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/important-investor-alert-lundin-law-pc-announces-a-securities-class-action-lawsuit-against-akari-therapeutics-plc-and-encourages-investors-with-losses-to-contact-the-firm-300460865.html

SOURCE Lundin Law PC